Zobrazeno 1 - 10
of 15
pro vyhledávání: '"F. D. Watanabe"'
Publikováno v:
Biotechnology and Bioengineering. 50:382-391
Despite recent advances in medical therapy, patients with fulminant hepatic failure (FHF) have a mortality rate approaching 90%. Many patients die because of failure to arrest the progression of cerebral edema. Liver transplantation has improved surv
Autor:
F. D. Watanabe, Achilles A. Demetriou, E. Kahaku, W. Hewitt, Susumu Eguchi, Yvette Middleton, Jacek Rozga, S. Chen
Publikováno v:
The International Journal of Artificial Organs. 19:664-669
UNLABELLED The only clinically proven effective treatment of fulminant hepatic failure (FHF) is orthotopic liver transplant (OLT). However, many patients die before an organ becomes available. Thus, there is a need for development of an extracorporea
Autor:
F. D. Watanabe, Achilles A. Demetriou
Publikováno v:
Current Opinion in Gastroenterology. 12:231-236
Autor:
Achilles A. Demetriou, F. D. Watanabe
Publikováno v:
Journal of Clinical Apheresis. 11:138-142
Autor:
Jonathan W. Said, F. D. Watanabe, Leonard Makowka, Robert L. Van de Velde, M.D. Philip Rosenthal, Eric A. Vasiliauskas, Jose Cocjin, Luis G. Podesta, Linda Sher, Robert Grier
Publikováno v:
Liver Transplantation and Surgery. 1:373-376
Orthotopic liver transplantation has been used to treat glycogen storage disease type IV. Most long-term surviving patients who have undergone liver transplantation have been free of neuromuscular and cardiac morbidity, and regression of cardiac amyl
Autor:
F. D. Watanabe, Philip J. Rosenthal
Publikováno v:
Current Opinion in Pediatrics. 7:533-538
Portal hypertension is an uncommon but serious complication in children. The etiology may be intrahepatic or from an extrahepatic vascular occlusion. The pathophysiology is unknown, but the development of increased vascular resistance and portal flow
Publikováno v:
American Journal of Critical Care. 3:224-227
Autor:
Theodore M. Khalili, F. D. Watanabe, Achilles A. Demetriou, E. Kahaku, Claudy J.-P. Mullon, W. Hewitt, Christopher R. Shackleton, Nicholas Arkadopoulos, Susumu Eguchi, Barry D. Solomon, Jacek Rozga, Walid S. Arnaout
OBJECTIVE: The purpose of this study was to develop a bioartificial liver (BAL) to treat patients with severe liver failure until they can be either transplanted or recover spontaneously. SUMMARY BACKGROUND DATA: Severe acute liver failure is associa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76b327ea94c8f65d5d57a905ff5b6365
https://europepmc.org/articles/PMC1190781/
https://europepmc.org/articles/PMC1190781/
Autor:
Ronald W. Busuttil, W. Hewitt, F. D. Watanabe, Steven D. Colquhoun, John M. Vierling, S.M. Cohen, Achilles A. Demetriou, D.E. Goldman, Tse-Ling Fong, Christopher R. Shackleton, Walid S. Arnaout
Publikováno v:
Transplantation proceedings. 29(1-2)
Autor:
S C, Chen, W R, Hewitt, F D, Watanabe, S, Eguchi, E, Kahaku, Y, Middleton, J, Rozga, A A, Demetriou
Publikováno v:
The International journal of artificial organs. 19(11)
The only clinically proven effective treatment of fulminant hepatic failure (FHF) is orthotopic liver transplant (OLT). However, many patients die before an organ becomes available. Thus, there is a need for development of an extracorporeal liver sup